Clinical trials: Hyperplasia Prostatic
Prostate Hypertrophy, Renal Disease
Effect of Deep BLock on Intraoperative Surgical Conditions
Rationale: A deep neuromuscular block is often associated with improved surgical conditions especially in laparoscopic surgery. However, a deep block comes at the expense of a variety of items that may conflict with the use of a…
- Trial name
- BLISS (NCT01631149)
- Testing
- Surgical block (rocuronium; atracurium/mivacurium)
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Leiden University Medical Center
Benign Prostatic Hyperplasia
Optilume™ BPH Catheter System in Men With Symptomatic BPH
PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic hyperplasia (BPH)
- Trial name
- PINNACLE (NCT04131907)
- Testing
- Optilume BPH Catheter System
- Where
- 21 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Urotronic Inc.
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
AVODART(Dutasteride) Post-marketing Surveillance(PMS)
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of AVODART administered in Korean BPH patients according to the prescribing information
- Trial name
- AVO PMS (NCT01299571)
- Testing
- Dutasteride
- Where
- South Korea
- Volunteers
- 3,977 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia (BPH)
Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
This is an open-labeled, non-randomized feasibility study to evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH).
- Trial name
- NCT02026908
- Testing
- Prostate Artery Embolization
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University
Prostatic Hyperplasia
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
The purpose of this study was to determine whether the daily consumption of decaffeinated green tea catechins (Polyphenon E®) for 1 year reduces the rate of progression to prostate cancer (PCa) in men diagnosed with HGPIN or…
- Trial name
- NCT00596011
- Testing
- Polyphenon E
- Where
- 10 sites in United States
- Volunteers
- 97 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Benign Prostatic Hyperplasia
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
The purpose of the study is to evaluate procedure tolerability and surgical recovery following the UroLift® system procedure when conducted with local anesthesia in subjects with symptomatic benign hyperplasia (BPH).
- Trial name
- LOCAL (NCT01876706)
- Testing
- UroLift® System
- Where
- 7 sites in United States
- Volunteers
- 51 people
- Sponsor
- NeoTract, Inc.
Benign Prostatic Hyperplasia
A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization
To gain clinical experience with the GreenLight HPS System, a system designed to vaporize and coagulate tissue in the treatment of benign prostatic hyperplasia to reduce lower urinary tract symptoms.
- Trial name
- PVP (NCT00465101)
- Testing
- GreenLight HPS
- Where
- 9 sites in United States
- Volunteers
- 150 people
- Sponsor
- American Medical Systems
Prostatic Hyperplasia
Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged…
- Trial name
- NCT01390870
- Testing
- 5ARI or AB or Combination Therapy (5ARI + AB)
- Volunteers
- 400 people
- Sponsor
- GlaxoSmithKline
Lower Urinary Tract Symptoms (LUTS)
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- DELUTS (NCT00947882)
- Testing
- Degarelix 10 mg, Degarelix 20 mg, Degarelix 30 mg
- Where
- 47 sites in United States, Belgium and 4 more
- Volunteers
- 404 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Hyperplasia
A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)
This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.
- Trial name
- NCT01003886
- Testing
- Doxazosin mesylate GITS
- Where
- 67 sites in Philippines
- Volunteers
- 989 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypogonadism, Benign Prostatic Hyperplasia
TRADE-Testosterone Replacement and Dutasteride Effectiveness
The purpose of this research study is to determine whether the combination of the male hormone testosterone [T] in gel form and the oral drug dutasteride [D], used to shrink large prostate glands can safely reduce the size of the…
- Trial name
- TRADE (NCT00194675)
- Testing
- Dutasteride, Testosterone gel
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Washington
Benign Prostatic Hyperplasia (BPH)
Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia
This is a Phase 4, prospective, open-label, randomized study of Greenlight XPS Laser versus BiVAP Saline Vaporization of the prostate in men with symptomatic Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT01500057
- Testing
- Greenlight XPS Laser, BiVAP Saline Vaporization of the prostate
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Brooklyn Urology Research Group
Prostatic Hyperplasia
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.
Two tamsulosin HClformulations will be tested in fed state
- Trial name
- NCT02417844
- Testing
- tamsulosin (Astellas), Tamsulosin HCL
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin
It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the volunteers receive, in each period, the test formulation or the reference formulation, under…
- Trial name
- NCT01330303
- Testing
- Reference formulation, Test formulation
- Where
- Brazil
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc
BPH
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
This exploratory study will be conducted open label in a single investigational clinical unit. Altogether 52 patients with benign prostate hyperplasia (BPH) will be randomly assigned to receive 4 different treatments with…
- Trial name
- NCT00527488
- Testing
- Degarelix
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- Ferring Pharmaceuticals
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS…
- Trial name
- Neptune (NCT01018511)
- Testing
- tamsulosin hydrochloride OCAS 0.4 mg, tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
- Where
- 118 sites in Austria, Belarus and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Astellas Pharma Europe B.V.
Benign Prostatic Hyperplasia
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
The purpose of the study is to evaluate the safety and effectiveness of the UroLift(R) System when used in subjects with symptomatic benign hyperplasia (BPH).
- Trial name
- LIFT (NCT01294150)
- Testing
- UroLift System, Cystoscopy, Crossover
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 206 people
- Sponsor
- NeoTract, Inc.
Prostatic Hyperplasia
Prospective Sexual Function Study for BPH Subjects
This is an European double-blind, placebo controlled parallel group comparison of DUODART (fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg, one capsule daily) and placebo.
- Trial name
- NCT01777269
- Testing
- Dutasteride plus tamsulosin
- Where
- 67 sites in Australia, France and 5 more
- Volunteers
- 489 people
- Sponsor
- GlaxoSmithKline